New drug treatment against non-severe malaria cases found to be effective
A new drug developed by researchers at Tulane University in the US is effective in treating non-severe cases of malaria. This comes as a significant development as public health experts warn that Plasmodium falciparum, the parasite responsible for most malaria cases, is developing resistance to widely used treatments.
New medications are needed to build up secondary defenses against drug-resistant strains of the parasite.
The new drug, called AQ-13, was able to clear the parasite responsible for the disease within a week, matching the effectiveness of the most widely used treatment regimen.
The results of the clinical trial, which was supervised by the US Food and Drug Administration (FDA), are “extraordinarily encouraging”, said Dr. Donald Krogstad, senior author and professor of tropical medicine at Tulane University School of Public Health and Tropical Medicine.
“Compared to the current first-line recommendation for treatment of malaria, the new drug comes out very well.”
Mosquitoes infected by a parasite spread malaria, causing more than 200 million illnesses across the globe and more than 400,000 deaths annually. For decades, chloroquine was used to treat malaria until Plasmodium falciparum developed resistance.
Now, a drug combination — artemether and lumefantrine — is the primary treatment for malaria although resistance is also developing to the drug combination in some countries.
Researchers recruited 66 adult men in Mali with uncomplicated malaria, which is defined as malaria that isn’t life threatening. Half were treated with AQ-13 and the other half received artemether and lumefantrine. Both drug groups had similar cure rates. However, five participants in AQ-13 group left the study or were lost to follow-up and two participants in the artemether/lumefantrine group had late treatment failures with recurrence of their original infections.
Researchers hope to expand testing of the drug to more participants, including women and children, before it can be widely recommended as a new treatment. Krogstad said that the same biotechnology that helped the team develop the new drug has also identified similar drugs that also hold promise against drug-resistant parasites.
“The potential long-term implications are bigger than one drug,” he said. “The conceptual step here is that if you understand the resistance well enough, you may be actually be able to develop others as well. We synthesized over 200 analogues and, of those, 66 worked against the resistant parasites.”
